ASPIRIN CARDIO

Land: Israël

Taal: Engels

Bron: Ministry of Health

Werkstoffen:

ACETYLSALICYLIC ACID

Beschikbaar vanaf:

BAYER ISRAEL LTD

ATC-code:

B01AC06

farmaceutische vorm:

TABLETS ENTERIC COATED

Samenstelling:

ACETYLSALICYLIC ACID 100 MG

Toedieningsweg:

PER OS

Prescription-type:

Not required

Geproduceerd door:

BAYER BITTERFELD GMBH, GERMANY

Therapeutische categorie:

ACETYLSALICYLIC ACID

Therapeutisch gebied:

ACETYLSALICYLIC ACID

therapeutische indicaties:

The primary prevention of coronary heart disease in patients at increased risk and the secondary prevention of thrombotic cerebrovascular or cardiovascular disease.

Autorisatie datum:

2015-02-28

Bijsluiter

[לוגו מדינת ישראל] [http://www.gov.il/]
[http://www.gov.il/] [לוגו משרד הבריאות] [לוגו משרד
הבריאות] [*5400]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
[http://www.health.gov.il/PniyotHazibur/Pages/CallCenter.aspx]
הציבור הרחב עסקים ומוסדות עובדים
בבריאות חפש מידע
תפריט *
[סגירה]
סגור *
דף הבית [http://www.health.gov.il/] *
אודות *
אודות המשרד
[http://www.health.gov.il/About/Pages/about_us.aspx] *
תוכנית עבודה
[http://www.health.gov.il/About/Pages/Agenda.aspx] *
תקציב המשרד
[http://www.health.gov.il/About/Pages/budget.aspx] *
תרשים מבנה ארגוני
[http://www.health.gov.il/About/Pages/OrganizationalStructureDiagram.aspx] *
בעלי תפקידים
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx] *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/About/Phonebook/Pages/PhoneBook.aspx?tab=3] *
אמנת שירות
[http://www.health.gov.il/About/sla/Pages/default.aspx] *
אותות ופרסים
[http://www.health.gov.il/About/Awards/Pages/mifal.aspx] *
פרוייקטים תשתיתיים
[http://www.health.gov.il/About/projects/shared_medical_info/Pages/default.aspx] *
דרושים
[http://www.health.gov.il/About/Careers/Pages/default.aspx] *
מנכ"לי משרד הבריאות לדורותיהם
[http://www.health.gov.il/About/Pages/GeneralManegerHistory.aspx] *
יחידות המשרד *
יחידות המשרד
[http://www.health.gov.il/UnitsOffice/Pages/UnitsList.aspx] *
לשכות הבריאות
[http://www.health.gov.il/UnitsOffice/LB/Pages/default.aspx] *
וועדות ומועצות
[http://www.health.gov.il/Services/Committee/Pages/CommitteeList.aspx] *
נושאים *
בריאות הנפש
[http://www.health.gov.il/Subjects/mental_health/Pages/default.aspx] *
בריאות הסביבה
[http://www.health.gov.il/Subjects/Environmental_Health/

Productkenmerken

SPC/Aspirin cardio
03/2016 PRESCRIBING INFORMATION
(SUMMARY OF PRODUCT CHARACTERISTICS / SPC)
1.
NAME OF DRUG PRODUCT
ASPIRIN CARDIO
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 enteric-coated tablet contains: 100 mg acetylsalicylic acid.
For a complete list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Enteric-coated tablets
4.
CLINICAL PARTICULARS
4.1 INDICATIONS
Aspirin® Cardio is indicated for the primary prevention of coronary
heart disease in patients
at
increased
risk
and
the
secondary
prevention
of
thrombotic
cerebrovascular
or
cardiovascular disease.
Note:
Aspirin Cardio is not suitable for the treatment of pain due to its
amount of active substance.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology:
A
daily
dose
of
one
Aspirin
Cardio
enteric-coated
tablet
(equivalent
to
100
mg
acetylsalicylic acid per day) is recommended.
Method of administration:
The gastro-resistant tablets should be taken with plenty of water
possibly at least 30
minutes before a meal. In order to ensure that the active substance is
released in the
alkaline environment of the intestine, the gastro-resistant tablets
should not be split,
crushed or chewed.
Aspirin cardio is intended for long-term use. The attending doctor
must decide on the length
of the treatment.
4.3
CONTRAINDICATIONS
Aspirin Cardio must not be used:
-
in cases of hypersensitivity to the active ingredient acetylsalicylic
acid, other salicylates
or any of the other ingredients listed in section 6.1.
-
by patients with a history of asthma attacks, which were caused by
salicylates or
substances
with
a
similar
action,
especially
nonsteroidal
anti-inflammatory
drugs
(NSAIDs).
-
by patients with acute gastrointestinal ulcers.
-
by patients with haemorrhagic diathesis.
-
by patients with liver or kidney failure.
-
by patients with severe heart failure for which they are not receiving
adequate treatment.
2
-
in combination with methotrexate at a weekly dosage of 15 mg or more
(see section
4.5).
-
in the last trimester of pregnancy at dosages above 150 mg
acetylsa